ProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary sessi...
Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.
ProQR Therapeutics (NASDAQ:PRQR) said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, initially focusing on
2026-09-30. The following slide deck was published by ProQR Therapeutics N.V.
ProQR Therapeutics (PRQR) said Wednesday it has dosed the first participant in a phase 1 trial of AX
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage ...
Buy ProQR Therapeutics N.V.: Axiomer RNA editing shows strong phase 1 proof-of-concept for biliary atresia; key 2026–27 catalysts ahead. Click to read more.
This is the newest page. Registered accounts read further back.